Vaxart Stock Discussion

$Vaxart (VXRT.US)$ Up she goes.

$Vaxart (VXRT.US)$ Let's go

$Vaxart (VXRT.US)$
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —
— The sentinel cohort is being funded as part of the Phase 2b NextGen COVID-19 clinical trial, valued at up to $456 million through the Rapid Response ...

$Vaxart (VXRT.US)$ Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

$Vaxart (VXRT.US)$
Analyst writes that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges.
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
“VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards,” the analyst writes.
“We think oral vaccines hold unique proper...

$Vaxart (VXRT.US)$
After hours, we can see this going to $1.05 and possibly $1.15

$Vaxart (VXRT.US)$
can see $1.15 coming

$Vaxart (VXRT.US)$
direct hit 🎯 $1.0

$Vaxart (VXRT.US)$
time to fly, looking for $1

$Vaxart (VXRT.US)$
Vaxart, Inc. (NASDAQ: VXRT) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. BARDA awarded Vaxart up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine.
2. The company plans to initiate the 10,000-subject Phase 2b trial in H2 2024, pending FDA alignment.
3. Vaxart is in discussions with the FDA regarding norovirus vaccine data and potential next steps.
4. Q2 2024 financial results: $62.6 million in cash and inv...